Literature DB >> 32353773

The association of serum lipid levels with colorectal cancer recurrence.

Kristen D Brantley1, Anders H Riis2, Rune Erichsen3, Ole Thorlacius-Ussing4, Holger Jon Møller5, Timothy L Lash6.   

Abstract

BACKGROUND: Biologic and epidemiologic evidence suggests that tumor cells depend on reprogrammed lipid metabolic function for survival and growth. Lipids may promote tumor recurrence by providing energy needed for proliferation. Studies have found associations of serum lipids with cancer incidence, mortality, and disease-free mortality, though they have yet to evaluate the prognostic potential of serum lipids for colorectal cancer (CRC) recurrence.
METHODS: 341 Danish CRC patients who underwent surgical resection were actively followed between 2003-2011 from date of surgery until December 31, 2012, or death. Serum lipids including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG), were collected at regular intervals. Lipids were assigned as time-varying exposures evaluated with a one-year lag. Cox proportional hazards models were used to assess recurrence rate, adjusting for clinically relevant covariates. A restricted analysis was performed in a group of non-statin users (n = 236).
RESULTS: Among 341 CRC patients, increased HDL-C appeared to have a beneficial impact on recurrence-free survival (RFS) for CRC patients, especially among statin users (hazard ratio [HR] for 0.1 mmol/L increase = 0.58; 95 % confidence interval [CI]: 0.43, 0.78). Increased LDL-C and TG were not associated with RFS. Increased lipids showed a near-null effect on CRC recurrence [e.g. HR (95 % CI) for 0.1 mmol/L increase LDL = 1.01 (0.97, 1.19)] among non-statin users.
CONCLUSION: Serum lipid levels of LDL-C and TG do not appear to be associated with CRC recurrence. Further investigation of the role of HDL-C in CRC recurrence may be of interest based on the suggestive inverse association observed here.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer recurrence; Cohort study; Colorectal cancer; Prognostic biomarkers; Serum lipids

Year:  2020        PMID: 32353773     DOI: 10.1016/j.canep.2020.101725

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  6 in total

1.  Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients.

Authors:  Jana Halámková; Lucia Bohovicová; Lucie Pehalová; Roman Goněc; Teodor Staněk; Tomáš Kazda; Lucie Mouková; Dagmar Adámková Krákorová; Šárka Kozáková; Marek Svoboda; Regina Demlová; Igor Kiss
Journal:  Cancers (Basel)       Date:  2022-03-27       Impact factor: 6.639

2.  Zinc Oxide Nanoparticle Inhibits Tumorigenesis of Renal Cell Carcinoma by Modulating Lipid Metabolism Targeting miR-454-3p to Repressing Metabolism Enzyme ACSL4.

Authors:  Xudong Zhou; Tingting Cao
Journal:  J Oncol       Date:  2022-03-25       Impact factor: 4.375

Review 3.  Reprogrammed Lipid Metabolism and the Lipid-Associated Hallmarks of Colorectal Cancer.

Authors:  Timothy Salita; Yepy H Rustam; Dmitri Mouradov; Oliver M Sieber; Gavin E Reid
Journal:  Cancers (Basel)       Date:  2022-07-29       Impact factor: 6.575

Review 4.  Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs.

Authors:  Kush K Patel; Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2021-06-12       Impact factor: 5.858

Review 5.  Revealing the Role of High-Density Lipoprotein in Colorectal Cancer.

Authors:  Aleksandra Zeljkovic; Jelena Vekic; Marija Mihajlovic; Tamara Gojkovic; Sandra Vladimirov; Dejan Zeljkovic; Vesna Spasojevic-Kalimanovska; Bratislav Trifunovic
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923

6.  Alcohol Consumption, HDL-Cholesterol and Incidence of Colon and Rectal Cancer: A Prospective Cohort Study Including 250,010 Participants.

Authors:  Aage Tverdal; Gudrun Høiseth; Per Magnus; Øyvind Næss; Randi Selmer; Gun Peggy Knudsen; Jørg Mørland
Journal:  Alcohol Alcohol       Date:  2021-10-29       Impact factor: 2.826

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.